Brief: Ocugen Announces Positive Preliminary Phase 2 Data From Ocu410 Modifier Gene Therapy For Geographic Atrophy Secondary To Dry Age-Related Macular Degeneration
15/01/2026 13:17
Jan 15 (Reuters) - Ocugen Inc OCGN.O: OCUGEN ANNOUNCES POSITIVE PRELIMINARY PHASE 2 DATA FROM OCU410 MODIFIER GENE THERAPY FOR GEOGRAPHIC ATROPHY SECONDARY TO DRY AGE-RELATED MACULAR DEGENERATION OCUGEN INC - NO SERIOUS ADVERSE EVENTS REPORTED IN PHASE 1 AND 2 TRIALS OCUGEN INC - PHASE 2 SHOWS 46% LESION GROWTH REDUCTION VERSUS CONTROL OCUGEN INC: REPORTING FULL DATA FROM OCU410 PHASE 2 CLINICAL TRIAL LATER THIS QUARTER AND INITIATING PHASE 3 IN 2026 OCUGEN INC: COMPANY REMAINS ON TRACK FOR A BIOLOGICS LICENSE APPLICATION (BLA) FILING FOR OCU410 IN 2028 Source text: ID:nGNX1yDLNm Further company coverage: OCGN.O ((Reuters.Briefs@thomsonreuters.com;))